Abstract
Background: It is known that calcium channel blockers are associated with a risk of gingival hyperplasia. These drugs are widely used in the management of gestational hypertensive disorders.
Case: A 27-year-old G1 woman presented with gingival hyperplasia at 27 weeks gestation during a hospitalisation for preeclampsia. She had been on nifedipine for hypertension for the last 9 weeks. Nifedipine was discontinued and replaced by methyldopa and already after 48 hours the gingival hyperplasia improved. She delivered two weeks later and the gingival hyperplasia resolved completely without surgical intervention. The Naranjo’s score was used to prove the nifedipine’s imputability. Conclusion: This first case report of gingival hyperplasia induced by nifedipine in pregnancy could be used as a reference for clinicians in the management of this adverse effect during the pregnancy.Keywords: Calcium channel blockers, dental management, gingival hyperplasia, nifedipine, preeclampsia, pregnancy.
Current Drug Safety
Title:Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report
Volume: 12 Issue: 1
Author(s): Brochet M.S., Harry M. and Morin F.
Affiliation:
Keywords: Calcium channel blockers, dental management, gingival hyperplasia, nifedipine, preeclampsia, pregnancy.
Abstract: Background: It is known that calcium channel blockers are associated with a risk of gingival hyperplasia. These drugs are widely used in the management of gestational hypertensive disorders.
Case: A 27-year-old G1 woman presented with gingival hyperplasia at 27 weeks gestation during a hospitalisation for preeclampsia. She had been on nifedipine for hypertension for the last 9 weeks. Nifedipine was discontinued and replaced by methyldopa and already after 48 hours the gingival hyperplasia improved. She delivered two weeks later and the gingival hyperplasia resolved completely without surgical intervention. The Naranjo’s score was used to prove the nifedipine’s imputability. Conclusion: This first case report of gingival hyperplasia induced by nifedipine in pregnancy could be used as a reference for clinicians in the management of this adverse effect during the pregnancy.Export Options
About this article
Cite this article as:
M.S. Brochet, M. Harry and F. Morin, Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666160426141851
DOI https://dx.doi.org/10.2174/1574886311666160426141851 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crucial Role of PDX-1 in Pancreas Development, β-Cell Differentiation, and Induction of Surrogate β-Cells
Current Medicinal Chemistry Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews α-Glucosidase Inhibitory Effect and Antioxidant Activity of the Extracts of Eighteen Plant Traditionally Used in Algeria for Diabetes
Current Enzyme Inhibition The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis
Current Vascular Pharmacology Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Lipid Metabolism and Nutrient Partitioning Strategies
Current Drug Targets - CNS & Neurological Disorders Peptidomics Biomarker Discovery in Mouse Models of Obesity and Type 2 Diabetes
Combinatorial Chemistry & High Throughput Screening Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain
Current Pharmaceutical Design Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Intracellular Fatty Acid Metabolism in Skeletal Muscle and Insulin Resistance
Current Diabetes Reviews Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Melatonin and its Relationships with Diabetes and Obesity: A Literature Review
Current Diabetes Reviews